Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 23, 2010
Cambridge, MA, November 23, 2010 - Epizyme, Inc., a company creating personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced that data related to the Company’s programs will be the subject of multiple oral presentations at the 52nd American Society of Hematology (ASH) Annual Mee...
Nov 15, 2010
Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, center...
Nov 3, 2010
Cambridge, MA, November 3, 2010 - Epizyme, Inc., a company leading the discovery and development of first‐in‐class, targeted cancer therapeutics against epigenetic targets, today announced that it has been awarded $733,437 in grants under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants are for t...
Jul 16, 2010
Cambridge, MA, July 16, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme...
May 14, 2010
Cambridge, MA, May 14, 2010 - Epizyme, Inc. announced today the appointment of Mikel Moyer, Ph.D., as Vice President of Molecular Discovery. He joins Epizyme from the Broad Institute, where he was Director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. Prior to the Broad, Dr. Moyer held leadership posi...
Mar 24, 2010
Cambridge, MA, March 24, 2010 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceuticals, announced today the appointment of Robert Gould, Ph.D. as Chief Executive Officer and of Jason Rhodes as Executive Vice President and Chief Business Officer. Dr. Gould h...
Dec 8, 2009
Cambridge, MA, December 8, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M. Epizyme initially announced a $32M ro...
Oct 20, 2009
Cambridge, MA, October 20, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today that Dr. Hoyoung Huh, President and CEO of BiPar Sciences, Inc., was appointed Epizyme's Chairman of the Board of Directors. Epizyme recently ann...
Oct 7, 2009
Cambridge, MA, October 7, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC). Joining BCC as new investors are Amgen Ventures and As...
Sep 9, 2009
Cambridge, MA, Sepetember 9, 2009 - A paper underscoring the importance of protein methyltransferases (PMTs) in drug discovery is published in the September 2009 online issue of NATURE REVIEWS DRUG DISCOVERY. Scientists Dr. Robert A. Copeland and Dr. Victoria M. Richon from Epizyme, Inc. in their paper entitled "Protein methyl...
= add release to Briefcase